Garrison Louis P, Kamal-Bahl Sachin, Towse Adrian
University of Washington, Seattle, WA, USA.
Pfizer, Inc., New York, New York, USA.
Value Health. 2017 Feb;20(2):213-216. doi: 10.1016/j.jval.2016.12.005.
This commentary identifies and defines potentially useful expansions to traditional cost-effectiveness analysis as often used in health technology assessment. Since the seminal 1977 article by Weinstein and Stason, the recommended approach has been the use of the incremental cost-effectiveness ratio based on the metric of the cost per quality-adjusted life-year gained, allowing comparisons across different technologies. An expanded framework, incorporating a wider range of the elements of value, is proposed. In addition to the core value drivers of health gain and other health system cost savings (if any), we propose adding other less recognized elements related to the value of knowing and informational externalities. We describe each of five factors related to the value of knowing: 1) a reduction in uncertainty, reflecting the benefit of a companion diagnostic increasing the certainty of a patient׳s response to a medicine; 2) insurance value related to greater peace of mind due to protection against catastrophic health and financial loss; 3) the value of hope for a "cure," leading individuals to become risk seekers in some circumstances; 4) real option value due to life extension opening possibilities for individuals to benefit from future innovation; and 5) spillovers or externalities arising from benefits of scientific advances that cannot be entirely appropriated by those making the advances. Further thought and research are needed on how best to measure and integrate these elements into an incremental value framework and on coverage and pricing decisions.
本评论确定并定义了对健康技术评估中常用的传统成本效益分析可能有用的扩展内容。自1977年温斯坦和斯塔森发表开创性文章以来,推荐的方法一直是使用基于每获得一个质量调整生命年成本这一指标的增量成本效益比,以便对不同技术进行比较。本文提出了一个扩展框架,纳入了更广泛的价值要素。除了健康收益和其他卫生系统成本节约(如有)等核心价值驱动因素外,我们建议增加与认知价值和信息外部性相关的其他较少被认可的要素。我们描述了与认知价值相关的五个因素:1)不确定性的降低,反映了伴随诊断增加患者对药物反应确定性的益处;2)保险价值,即由于防范灾难性健康和财务损失而带来的更大安心感;3)“治愈”希望的价值,导致个体在某些情况下成为风险寻求者;4)由于生命延长为个体从未来创新中受益创造可能性而产生的实物期权价值;5)科学进步的益处所产生的溢出效应或外部性,这些益处无法被取得进步者完全占有。关于如何最好地衡量这些要素并将其纳入增量价值框架以及覆盖范围和定价决策,还需要进一步思考和研究。